Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- DNA.NYSE
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Ginkgo Bioworks (DNA) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$6.38
-19.0%5-Year
PARTIAL SELL$5.78
-26.6%Published batch insight
Biological Platform Pivot Confronts Severe Cash Burn And Permanent Share Dilution
A high consensus emerges across independent reports that aggressive cost rationalization and autonomous laboratory deployments will ensure operational survival. However, persistent quarterly cash burn, unyielding facility lease obligations, and relentless at-the-market share dilution will permanently limit per-share equity recovery over the five-year forecast horizon.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Superintelligence (Anthropologist), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Universal Investor (Polymath), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTFull published thesis
Executive Summary
If you invested $10,000 in Ginkgo Bioworks at the forecast anchor (2026-09-18): $7,339 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 7.31 | -7.28% | -7.28% | Third-quarter results reflect continued top-line contraction across legacy cell programs following biosecurity deconsolidation. Persistent cash burn and year-end tax-loss selling across unprofitable life science platforms generate moderate valuation compression despite initial overhead savings. |
| Q1 2027 | 6.76 | -7.50% | -14.23% | Audited full-year results confirm annual continuing revenue near eighty million dollars. Management guidance indicates ongoing cash consumption into 2027, prompting equity markets to discount shares as unabsorbed facility lease costs outpace administrative reductions. |
| Q2 2027 | 6.91 | +2.26% | -12.29% | Initial commercial revenue recognition from autonomous lab installations and standardized pharmacokinetic assay panels provides tactical support. Short covering and evidence of halved operating expenses generate a modest seasonal rebound off oversold valuation levels. |
| Q3 2027 | 6.38 | -7.68% | -19.03% | Working capital demands from customized laboratory deployments coincide with active at-the-market equity issuances. The resulting expansion in outstanding share count exerts downward mechanical pressure on per-share valuations as credit markets remain restrictive. |
| Q4 2027 | 6.00 | -5.99% | -23.88% | Unrestricted liquid reserves approach the two-hundred-million-dollar threshold, intensifying market focus on balance-sheet runway. Macroeconomic borrowing costs sustain pressure on early-stage biotechnology outsourcing, triggering institutional tax-loss rebalancing and price softening. |
| Q1 2028 | 5.90 | -1.69% | -25.17% | Execution of structured secondary equity issuance replenishes cash balances but dilutes existing shareholders. Investors digest the expanded share base, though operational disclosures show quarterly cash burn successfully compressed below thirty million dollars. |
| Q2 2028 | 5.92 | +0.37% | -24.90% | Expanding autonomous cloud laboratory utilization across academic consortia and federal agencies yields steady service receipts. Narrowed EBITDA losses and baseline contract stability encourage contrarian institutional accumulation at depressed price-to-book valuation multiples. |
| Q3 2028 | 5.60 | -5.38% | -28.94% | Delivery timing on specialized hardware deployments introduces quarterly revenue volatility. Operating lease encumbrances continue to weigh on GAAP margins, blunting earlier enthusiasm and prompting sideways consolidation across public equity trading. |
| Q4 2028 | 5.60 | +0.08% | -28.89% | Incremental partner milestone achievements from legacy collaborative pipelines inject non-dilutive gross profit. A cyclical stabilization in biotech venture funding supports forward booking visibility, prompting a moderate relief advance into year-end. |
| Q1 2029 | 5.66 | +0.98% | -28.19% | Annual reporting verifies operating losses decreased significantly as automated workcells replace manual bench research. Improved cash conversion and stabilizing liquidity reserves allow the equity to maintain a firmer fundamental valuation baseline. |
| Q2 2029 | 5.75 | +1.57% | -27.06% | Commercial adoption of standardized assay testing accelerates under domestic supply-chain security initiatives. Sequential top-line expansion across enterprise biopharma accounts validates the lab-as-a-service transition, driving measured enterprise multiple re-rating. |
| Q3 2029 | 5.62 | -2.27% | -28.72% | Competitive pricing from domestic and overseas contract research organizations limits realized assay margins. The market pauses its multiple expansion, demanding evidence that physical laboratory robotics can generate sustained economic owner earnings. |
| Q4 2029 | 5.68 | +1.10% | -27.94% | Consumables utilization and recurring software maintenance contracts across installed Nebula sites provide revenue stability. Approaching operational cash-flow parity removes residual solvency discounts, supporting modest upward drift in quoted equity pricing. |
| Q1 2030 | 5.65 | -0.56% | -28.34% | Full-year results confirm organic top-line recovery crossing one hundred twenty million dollars. While equity compensation and prior financing expand the share denominator, operational durability fosters renewed interest from fundamental healthcare turnaround investors. |
| Q2 2030 | 5.75 | +1.75% | -27.09% | High-throughput autonomous laboratory utilization surpasses seventy percent across core facilities. High incremental gross margins on routine assay runs begin absorbing fixed facility depreciation, generating tangible progress toward GAAP operating breakeven. |
| Q3 2030 | 5.67 | -1.36% | -28.07% | Modest capital expenditure requirements for robotic hardware maintenance and sensor upgrades absorb working capital. Range-bound trading prevails as investors weigh ongoing capital intensity against stabilized single-digit top-line revenue growth. |
| Q4 2030 | 5.67 | -0.03% | -28.10% | Securing multi-year federal bio-preparedness infrastructure contracts bolsters long-term cash flow predictability. Positive adjusted EBITDA prints solidify market perception of the asset as an established, specialized life science automation utility. |
| Q1 2031 | 5.70 | +0.64% | -27.63% | Audited accounts demonstrate sustainable operating self-sufficiency with minimal quarterly cash consumption. The elimination of existential balance-sheet dilution risks allows shares to consolidate firmly at revised contract-research valuation benchmarks. |
| Q2 2031 | 5.76 | +1.08% | -26.85% | Steady commercial execution in outsourced automated cell engineering generates modest free cash flow. Quoted equity prices reflect balanced institutional trading, recognizing operational survival alongside permanent historic share count dilution. |
| Q3 2031 | 5.78 | +0.34% | -26.61% | Five-year corporate reset concludes with the enterprise settled as a cash-disciplined biological automation provider. Valuation multiples reflect mature contract-service peers, fully balancing demonstrated robotic operational capabilities against a substantially expanded share base. |
The base-case economic reality reflects a capital-intensive laboratory automation provider successfully executing survival restructuring while diluting per-share owner economics. The complete deconsolidation of pandemic-era biosecurity testing has contracted continuing revenue to an annualized run rate near $80 million. Although management has aggressively halved research payroll and consolidated laboratory footprints to compress annual cash burn toward $125 million to $150 million, fixed operating lease liabilities exceeding $400 million and substantial facility depreciation create severe negative operating leverage. Trading around 2.3 times continuing sales on enterprise value, the equity is highly sensitive to the velocity of at-the-market dilution, which steadily transfers asset-backed value from existing holders to incoming liquidity providers before operational breakeven arrives. The central counterargument posits that sovereign biosecurity mandates and autonomous lab validation will accelerate high-margin licensing, yet statutory safe harbors and venture capital retrenchment ensure that commercial onshoring demand materializes incrementally rather than immediately.
Key insights
- Operating lease commitments of $404 million represent inflexible senior claims that outlast headcount reductions, preventing swift GAAP profitability.
- Relentless at-the-market share issuance continuously dilutes net liquid asset backing, capping per-share recovery despite operational improvements.
- Commercializing autonomous laboratory hardware shifts the enterprise toward commoditized contract research, permanently precluding software-like platform valuation multiples.
The company is transforming from an overhyped science incubator into a practical, automated laboratory service provider. After its COVID-era testing business vanished, annual sales dropped sharply to around $80 million. Management has cut operating costs aggressively to save cash, but running large robotic laboratories still burns significant money each quarter. While the company holds enough cash to avoid near-term bankruptcy, it relies on selling new shares to fund operations, which continuously reduces the ownership slice of existing stockholders.
Key insights
- Heavy lease costs on large laboratory buildings remain an expensive ongoing burden despite recent staff cuts.
- Selling new shares into the market continually lowers per-share cash value and limits stock price gains.
- Shifting into contract laboratory services means earning standard industrial margins rather than high software-like profits.
Deep Dive
Prevailing market consensus views the company as a busted post-SPAC platform whose original cellular programming vision collapsed alongside biosecurity testing revenues. Media coverage and sell-side analysts anchor heavily on sixty percent top-line contraction and persistent negative cash flow, pricing the equity as a melting cash shell facing inevitable capital depletion. The outside crowd discounts the autonomous laboratory pivot as conceptual theater, assuming platform unit economics are fundamentally unviable.